PARP inhibitors have recently been FDA approved for breast cancer patients with germline mutations in DNA repair genes, specifically those with deleterious BRCA1 and BRCA2 mutations, which constitutes 3–4% of all women with breast cancer and includes 10 to 20% of those with triple-negative breast cancer [3–10]. Here, PARP1 is linked to breast carcinoma.